Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Non-Current Liabilities: 2014-2025

Historic Total Non-Current Liabilities for Gyre Therapeutics (GYRE) over the last 4 years, with Sep 2025 value amounting to $18.7 million.

  • Gyre Therapeutics' Total Non-Current Liabilities rose 17.13% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year increase of 17.13%. This contributed to the annual value of $16.4 million for FY2024, which is 20.15% down from last year.
  • Per Gyre Therapeutics' latest filing, its Total Non-Current Liabilities stood at $18.7 million for Q3 2025, which was down 6.28% from $20.0 million recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Total Non-Current Liabilities high stood at $22.1 million for Q1 2025, and its period low was $1.8 million during Q3 2023.
  • In the last 3 years, Gyre Therapeutics' Total Non-Current Liabilities had a median value of $17.1 million in 2024 and averaged $14.3 million.
  • Examining YoY changes over the last 5 years, Gyre Therapeutics' Total Non-Current Liabilities showed a top increase of 979.83% in 2024 and a maximum decrease of 20.15% in 2024.
  • Quarterly analysis of 4 years shows Gyre Therapeutics' Total Non-Current Liabilities stood at $12.5 million in 2022, then spiked by 64.31% to $20.5 million in 2023, then declined by 20.15% to $16.4 million in 2024, then increased by 17.13% to $18.7 million in 2025.
  • Its Total Non-Current Liabilities was $18.7 million in Q3 2025, compared to $20.0 million in Q2 2025 and $22.1 million in Q1 2025.